Ipsen – Consolidated Financial Statements – 2022

Announcement 11 July 2024 6 mins read

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

Press Releases 09 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024

Press Releases 09 July 2024 1 mins read

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Press Releases 08 July 2024 1 mins read

Half-year statement of IPSEN liquidity agreement – 2024 06 30

Press Releases 02 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024

Corporate 02 July 2024 9 mins read

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

Press Releases 25 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024

Press Releases 18 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

Press Releases 11 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024

Corporate 10 June 2024 12 mins read

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis